The anti-hPD-L1 isotype family features the variable region of atezolizumab. Atezolizumab (also known as MPDL3280A) is a fully humanized IgG1 (N298A) monoclonal antibody that targets the programmed cell death ligand 1 (PD-L1), a transmembrane protein over-expressed on tumor cells and tumor infiltrating immune cells, such as macrophages. PD-L1 binds to programmed cell death protein 1 (PD-1) on cytotoxic T cells, inhibiting the antitumor immune response. Atezolizumab blocks the interaction of PD-L1 with PD-1 and induces anti-tumor immune reactivation. This mAb contains an Asp to Ala change introduced at position 298 (N298A) eliminating its ability to bind to human Fcγ receptors.
FDA has granted atezolizumab priority review for advanced bladder cancer.
Atezolizumab targets both human and mouse PD-L1. For studies in mice, InvivoGen has developed anti-hPD-L1-mIgG1, an antibody that contains the variable region of atezolizumab and the Fc domain of mouse IgG1 to prevent anti-drug-antibodies (ADAs).
The anti-hPD-L1 isotype family has been generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography.
More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see below or in the 'upon request' section).
